PET Imaging of VLA-4 in a New BRAF^V600E Mouse Model of Melanoma.

ABSTRACT:

Purpose

Despite unprecedented responses to immune checkpoint inhibitors and targeted therapy in melanoma, a major subset of patients progresses and have few effective salvage options. We have previously demonstrated robust, selective uptake of the peptidomimetic LLP2A labeled with Cu-64 ([⁶⁴Cu]-LLP2A) for positron emission tomography (PET) imaging in subcutaneous and metastatic models of B16F10 murine melanoma. LLP2A binds with high affinity to very late antigen-4 (VLA-4, integrin α₄β₁), a transmembrane protein overexpressed in melanoma and other cancers that facilitates tumor growth and metastasis. Yet B16F10 fails to faithfully reflect human melanoma biology, as it lacks certain oncogenic driver mutations, including BRAF mutations found in ≥ 50 %

SUBMITTER: Bellavia MC 

PROVIDER: S-EPMC9183947 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature